Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A

Cancer Research

Volumn 66, Issue 2, 2006, Pages 1177-1180

  Lesueur, Fabienne ^a   Cebrian, Arancha ^a   Robledo, Mercedes ^c   Niccoli Sire, Patricia ^d   Svensson, Karl Axel ^e   Pinson, Stephane ^f   Leyland, Jean ^a   Whittaker, Joanne ^b   Pharoah, Paul D ^a   Ponder, Bruce A J ^a,g  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d TIMONE HOSPITAL   (France)

^e Ljungby Hospital   (Sweden)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GUANINE; LIGAND; PROTEIN RET; RECEPTOR; SERINE;

ADULT; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA MODIFICATION; EUROPE; GENETIC POLYMORPHISM; GERM LINE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; ONCOGENE RET; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA;

ADULT; AGE OF ONSET; CARCINOMA, MEDULLARY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; LIGANDS; MALE; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MUTATION, MISSENSE; PEDIGREE; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-RET; RECEPTORS, CELL SURFACE; THYROID NEOPLASMS;

EID: 31544434233     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2995     Document Type: Article

References (9)

1. Mulligan LM, Ponder BA. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 1995;80:1989-95.
2. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276: 1575-9.
3. Cebrian A, Lesueur F, Martin S, et al. Polymorphisms in the initiators of RET signalling pathway and susceptibility to sporadic medullary thyroid carcinoma. JCEM 2005;90:6268-74.
4. Robledo M, Gil L, Pollan M, et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003;63:1814-7.
5. Niccoli-Sire P, Murat A, Rohmer V, et al. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients. J Clin Endocrinol Metab 2001;86:3746-53.
6. Gil L, Azanedo M, Pollan M, et al. Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A. Int J Cancer 2002;99:299-304.
7. Rossella E, Cosci B, Romei C, et al. RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004;89: 3579-84.
8. Anders J, Kjar S, Ibanez CF. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem 2001;276:35808-17.
9. Duan J, Wainwright MS, Comeron JM, et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003;12:205-16.